Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Enbrel (etanercept by Year
Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — Worldwide product sales ($M) ($M)
Amgen Enbrel (etanercept: $2,226M in FY2025, down 32.9% from a year earlier. That is the lowest of the 11 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,226 | -32.9% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 3,316 | -10.3% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 3,697 | -10.2% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 4,117 | -7.8% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 4,465 | -10.6% | Form 10-K (filed 2024-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 4,996 | -4.4% | Form 10-K (filed 2023-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 5,226 | +4.2% | Form 10-K (filed 2022-02-16) ↗ |
| FY2018 | Dec 31, 2018 | 5,014 | -7.7% | Form 10-K (filed 2021-02-09) ↗ |
| FY2017 | Dec 31, 2017 | 5,433 | -8.9% | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 5,965 | +11.2% | Form 10-K (filed 2019-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 5,364 | – | Form 10-K (filed 2018-02-13) ↗ |
Breakdown
What makes up enbrel (etanercept
- Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — U.S. product sales ($M)2,199 · FY2025
- Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — Rest of World (ROW) product sales ($M)27 · FY2025
- Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — Worldwide reported sales growth YoY (%)-33.0% · FY2025
- Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — Worldwide net selling price change YoY (%)-36.0% · FY2025
Cite this data
StockData. (2026). Amgen Enbrel (etanercept ($M), annual FY2015–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-enbrel-ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.